trending Market Intelligence /marketintelligence/en/news-insights/trending/mrcey1lcwwqjujhpnynnqw2 content esgSubNav
In This List

Biolase regains Nasdaq compliance

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Biolase regains Nasdaq compliance

Biolase Inc. said it regained compliance with the Nasdaq Capital Market's $1 minimum bid price listing requirement.

The Irvine, Calif.-based medical device company recently implemented a 1-for-5 reverse stock split to regain compliance.

Biolase received the noncompliance notice in August 2017. The company failed to raise its bid price in time, but it was granted a 180-day extension to regain compliance.